How Pluvicto Targets Prostate Cancer Cells
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) treats prostate cancer by delivering targeted radiation to cancer cells. It combines a small molecule called PSMA-617, which binds specifically to prostate-specific membrane antigen (PSMA) on prostate cancer cells, with the radioactive isotope lutetium-177 (Lu-177). PSMA is overexpressed in most metastatic castration-resistant prostate cancers (mCRPC), making it an ideal target.[1][2]
Once injected, Pluvicto circulates and attaches to PSMA on tumor cells and their metastases, including in bones and lymph nodes. The attached Lu-177 then emits beta radiation, damaging the cancer cell's DNA and causing cell death. Healthy PSMA-expressing tissues like salivary glands or kidneys receive lower doses due to rapid clearance and protective measures like amino acid infusions.[1][3]
Who Qualifies for Pluvicto Treatment
Pluvicto is approved for adults with PSMA-positive mCRPC that has progressed after androgen receptor pathway inhibition (ARPI) and taxane-based chemotherapy. Patients must first undergo a PSMA-PET scan to confirm high PSMA expression (e.g., SUVmax ≥4 on at least one lesion).[1][4]
Treatment involves intravenous infusions every 6 weeks, up to 6 cycles, with each dose around 7.4 GBq (200 mCi). Doctors monitor PSMA-PET or PSA levels to assess response.[2]
How Effective Is Pluvicto in Trials
In the VISION trial, Pluvicto plus best standard of care extended overall survival by 4 months (15.3 vs. 11.3 months) and radiographic progression-free survival by 5.1 months compared to standard care alone. PSA levels dropped ≥50% in 46% of Pluvicto patients vs. 22% in controls. Benefits held across subgroups, including those with liver metastases.[1][5]
Real-world data shows similar PSA declines and survival gains, though long-term outcomes depend on disease burden.[3]
What Side Effects Do Patients Experience
Common side effects include dry mouth (30-40%), fatigue, nausea, anemia, and kidney function decline. Serious risks involve bone marrow suppression (leading to low blood counts), urinary obstruction, and rare fractures. Most effects are manageable; salivary gland symptoms often improve over time.[1][2]
Patients on blood thinners or with poor kidney function need closer monitoring.
How Pluvicto Fits with Other Prostate Cancer Treatments
Pluvicto is a radioligand therapy, distinct from chemotherapy or immunotherapy. It follows ARPIs (e.g., enzalutamide) and taxanes (e.g., cabazitaxel), often after Pluvicto's cousin, Pluvicto's precursor in trials. Ongoing studies test it earlier, like with ARPIs (PSMAfore trial) or in hormone-sensitive disease (PSMAddition). It pairs with radiation or surgery in select cases but isn't first-line.[4][5]
No generic or biosimilar exists yet.
When Does Pluvicto's Patent Protection End
Pluvicto's key composition-of-matter patent (US 10,808,040 for the Lu-177-PSMA conjugate) expires in 2037, with formulation patents extending to 2040. Pediatric exclusivity adds 6 months. Novartis holds multiple PSMA-related patents, facing challenges from competitors like Bayer (in licensing deals). Check DrugPatentWatch.com for litigation updates and exact expiry dates.[6]
[1] Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Prescribing Information, Novartis, 2022.
[2] FDA Approval Summary for Pluvicto, Oncology (Williston Park), 2022.
[3] VISION Trial Results, New England Journal of Medicine, 2021.
[4] NCCN Guidelines for Prostate Cancer, Version 3.2024.
[5] ESMO Clinical Trial Updates on Pluvicto, Annals of Oncology, 2023.
[6] DrugPatentWatch.com, Lutetium Lu 177 Vipivotide Tetraxetan Patents (accessed 2024).